Skip to main content
Premium Trial:

Request an Annual Quote

Paul Grint, Scott Greer, Andre Hoekema, Bruce Kimmel, David Weber

Premium

Illumina has appointed Paul Grint to its board of directors. Grint is currently senior vice president and chief medical officer of Zephyr Sciences, a biopharmaceutical company. He received his MD from the University of London, St. Bartholomew's Hospital Medical College.

Illumina also announced the April 12 resignation of director Scott Greer, chairman of Abgenics, an Illumina director since May 2001.


Galapagos has appointed Andre Hoekema as managing director of Galadeno, Galapagos' services unit. Galadeno performs target discovery using adenoviral siRNA technologies.

Hoekema, 47, joins Galapagos from Invitrogen, where he served as the managing director of corporate development in Europe.


Ambrx has appointed Bruce Kimmel as vice president of therapeutic applications. He obtained his PhD in biochemistry from the University of California, Berkeley, and conducted postdoctoral work at UCSF.


Stratagene has hired David Weber as its new senior vice president of marketing. He comes to Stratagene from GE Healthcare, where he was president, Region Americas, where he managed sales for the United States, Canada, and Latin America. Weber earned a BS in biochemistry from Rutgers University.

Filed under

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.